Loading...
Loading...
CHRS| Name | Value |
|---|---|
| Revenues | 58.7M |
| Cost of Revenue | 24.8M |
| Gross Profit | 33.9M |
| Operating Expense | 68.4M |
| Operating I/L | -34.5M |
| Other Income/Expense | -8.3M |
| Interest Income | 9.9M |
| Pretax | -42.9M |
| Income Tax Expense | 11.6M |
| Net Income/Loss | -42.9M |
Coherus BioSciences, Inc. is a biopharmaceutical company specializing in biosimilars and immuno-oncology products in the United States. The company's flagship product, UDENYCA, is a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor. Coherus BioSciences also has a robust pipeline of biosimilars including Humira, Avastin, and Lucentis. Additionally, the company is developing innovative products such as Toripalimab, a novel anti-PD-1 antibody for melanoma treatment, and biosimilars of Bevacizumab, adalimumab, and ranibizumab. Coherus BioSciences has established license agreements with prominent biopharmaceutical companies, driving its revenue through product sales and licensing partnerships.
